跳到正文
David H Aggen, MD PhD· @Dr_Aggen · X·· 1 天前评分70

VOLGA

正文 · 原文

With VOLGA results coming at #ESMO26, a summary of contemporary phase III perioperative trials in muscle-invasive bladder cancer.

⚠️ Different populations and designs—avoid cross-trial comparisons. VOLGA and EV-303 importantly include surgery-alone control arms without neoadjuvant therapy.

🔑 The next challenge: identifying who truly needs adjuvant ADC therapy—and who can safely avoid it.

#BladderCancer #GUOnc @OncoAlert @BladderCancerUS

16 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要
LBA2按 Presidential Symposium I 对上

Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial

https://esmocongress.esmo.org

来源:David H Aggen, MD PhD · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org